Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Review Article

Aloe-emodin: Progress in Pharmacological Activity, Safety, and Pharmaceutical Formulation Applications

Author(s): Haimeng Luo, Xiaoyun Ji, Mengyu Zhang, Yaoyao Ren, Rui Tan*, Hezhong Jiang* and Xiaoqing Wu*

Volume 24, Issue 19, 2024

Published on: 18 April, 2024

Page: [1784 - 1798] Pages: 15

DOI: 10.2174/0113895575298364240409064833

Price: $65

Abstract

Aloe-emodin (AE) is an anthraquinone derivative and a biologically active component sourced from various plants, including Rheum palmatum L. and Aloe vera. Known chemically as 1,8-dihydroxy-3-hydroxymethyl-anthraquinone, AE has a rich history in traditional medicine and is esteemed for its accessibility, safety, affordability, and effectiveness. AE boasts multiple biochemical and pharmacological properties, such as strong antibacterial, antioxidant, and antitumor effects. Despite its array of benefits, AE's identity as an anthraquinone derivative raises concerns about its potential for liver and kidney toxicity. Nevertheless, AE is considered a promising drug candidate due to its significant bioactivities and cost efficiency. Recent research has highlighted that nanoformulated AE may enhance drug delivery, biocompatibility, and pharmacological benefits, offering a novel approach to drug design. This review delves into AE's pharmacological impacts, mechanisms, pharmacokinetics, and safety profile, incorporating insights from studies on its nanoformulations. The goal is to outline the burgeoning research in this area and to support the ongoing development and utilization of AE-based therapies.

Keywords: Aloe-emodin, pharmacological, mechanism, pharmacokinetics, safety, nanoformulation, AE-based therapies.

« Previous
Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy